Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29785429 | 1.00 | PLAT (0.32) | PLATDHODHHSP90AA1GAAMAPT | |
| SCHEMBL24834764 | 1.00 | PLAT (0.32) | PLATDHODHHSP90AA1GAAMAPT | |
| SCHEMBL24834785 | 0.99 | PLAT (0.32) | PLAT | |
| SCHEMBL29785428 | 0.99 | PLAT (0.32) | PLAT | |
| SCHEMBL24834991 | 0.94 | DGAT1 (0.31) | PLAT | |
| SCHEMBL24834854 | 0.94 | DGAT1 (0.31) | PLAT | |
| SCHEMBL23415491 | 0.90 | PLAT (0.30) | PLAT | |
| SCHEMBL24834767 | 0.90 | PLAT (0.30) | PLAT | |
| SCHEMBL24834907 | 0.90 | PLAT (0.30) | PLAT | |
| SCHEMBL29785490 | 0.90 | PLAT (0.30) | PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054190-A1 | PHARMACEUTICAL FORMULATIONS AND DOSING SCHEDULES OF A YAP/TAZ-TEAD INHIBITOR | VIVACE THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | claimed |
| WO-2025054190-A1 | PHARMACEUTICAL FORMULATIONS AND DOSING SCHEDULES OF A YAP/TAZ-TEAD INHIBITOR | VIVACE THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20240148733-A1 | COMBINATION THERAPY | GENENTECH INC (US) | 2024-05-09 | — | — | US | disclosed |
| EP-4340883-A1 | COMBINATION THERAPY | GENENTECH, INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117337193-A | combination therapy | 基因泰克公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2022246459-A9 | COMBINATION THERAPY | GENENTECH, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022246459-A1 | COMBINATION THERAPY | GENENTECH, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| CN-114786778-A | Therapeutic compounds | 基因泰克公司 | 2022-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148733-A1 | COMBINATION THERAPY | KRAS, YAP1, HRAS | PLAT 1750/4885DHODH 3121/4885HSP90AA1 1530/4885 |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | YAP1, YES1, TEAD2 | PLAT 3745/4885DHODH 3349/4885HSP90AA1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.